SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
release, which, among other matters, sets forth our results of
operations for the quarter ended March 31, 2017. A copy of the
press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
furnished under Item 2.02 and shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, or otherwise subject to the liability of that section,
nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such a filing.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release dated May 2, 2017
|
About SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI)
Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin’s lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has two drugs in late-stage development: SPI-2012, which is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. It has a product portfolio consisting of both commercial-stage and development-stage products that address various cancer types. Its commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. Its other products include SPI-2012, POZIOTINIB and EOQUIN. SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI) Recent Trading Information
SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI) closed its last trading session down -0.17 at 7.53 with 682,315 shares trading hands.
